Pancreatic Cell News Volume 14.47 | Dec 6 2022

December 6, 2022

2022-12-06 | PACN 13.47

Pancreatic Cell News by STEMCELL Technologies

Vol. 13.47 – 6 December, 2022

TOP STORY

Neuronal-Epithelial Cross-Talk Drives Acinar Specification via NRG1-ERBB3-mTORC2 Signaling

Scientists demonstrated that neuronal-epithelial cross-talk drove acinar specification through neuregulin-ERBB3-mTORC2 signaling.
[Developmental Cell]

Full Article Graphical Abstract

Five tips for returning to the lab after time off

PUBLICATIONSRanked by the impact factor of the journal

DIABETES & PANCREATITIS

Extracellular SQSTM1 Exacerbates Acute Pancreatitis by Activating Autophagy-Dependent Ferroptosis

Scientists reported that extracellular sequestosome 1 (SQSTM1) acted as a mediator of acute pancreatitis by enhancing the sensitivity to autophagy-dependent ferroptotic cell death.
[Autophagy]

Abstract

Glycemic Control Releases Regenerative Potential of Pancreatic Beta Cells Blocked by Severe Hyperglycemia

Investigators identified and characterized heterogeneity in response to beta cell ablation. Efficient beta cell elimination leading to severe hyperglycemia, caused permanent diabetes with failed regeneration despite cell cycle engagement of surviving beta cells.
[Cell Reports]

Full Article Graphical Abstract

RNA Binding Protein HUD Mediates the Crosstalk between β Cells and Islet Endothelial Cells by the Regulation of Endostatin and Serpin E1 Expression

Co-cultures of βTC6 cells and pancreatic islet endothelial MS1 cells were used to assess the crosstalk between β cells and islet endothelial cells, and the results showed that HuD downregulation in βTC6 cells inhibited the growth and migration of MS1 cells.
[Cell Death & Disease]

Full Article

Diphenyl Ether Derivatives as Novel GPR120 Agonists for the Treatment of Type 2 Diabetes Mellitus

Researchers designed and synthesized a series of novel GPR120 agonists based on the structure of TUG-891, which was the first potent and selective GPR120 agonist.
[Chemistry & Biodiversity]

Abstract

PANCREATIC CANCER

Elevated FSP1 Protects KRAS-Mutated Cells from Ferroptosis during Tumor Initiation

The authors found that pharmacological induction of ferroptosis in pancreatic organoids derived from the LsL-KRASG12D expressing mouse model was only effective in combination with ferroptosis suppressor protein 1 (FSP1) inhibition.
[Cell Death & Differentiation]

Full Article

BRAF^V600E in Colorectal Cancer Reduces Sensitivity to Oxidative Stress and Promotes Site-Specific Metastasis by Stimulating Glutathione Synthesis

BRAF^V600E tumors and patient-derived organoids express high levels of glutamate-cysteine ligase (GCL), the rate-limiting enzyme in glutathione synthesis. Deletion of GCL in BRAF^V600E PDOs strongly reduced their capacity to form distant liver and lung metastases but did not affect peritoneal metastasis outgrowth.
[Cell Reports]

Full Article Graphical Abstract

Assessment of Stromal SCD-Induced Drug Resistance of PDAC Using 3D-Printed zPDX Model Chips

The mixture of cancer-associated fibroblasts and cancer cells were co-injected into scd^-/-; prkdc^-/-, or hIGF1/INS-expressing zebrafish to generate patient-derived xenograft models.
[iScience]

Abstract Full Article Graphical Abstract

Mesenchymal-Endothelial Nexus in Breast Cancer Spheroids Induces Vasculogenesis and Local Invasion in a CAM Model

Using a spheroid system composed of breast cancer cells (BCC) with defined human mesenchymal stem cell and endothelial cell fractions, scientists showed that endothelial cell organization into vascular structures is BC phenotype dependent, and independent of ERα expression in epithelial cancer cells.
[Communications Biology]

Full Article

REVIEWS

Novel Histone Post-Translational Modifications in Diabetes and Complications of Diabetes: The Underlying Mechanisms and Implications

Scientists summarize the relationship between novel histone modifications and diabetes, mainly focusing on β-hydroxybutyrylation, propionylation, butyrylation, malonylation, and succinylation.
[Biomedicine & Pharmacotherapy]

Abstract

Therapeutic Strategies Targeting Pancreatic Islet β-Cell Proliferation, Regeneration, and Replacement

The authors highlight important findings in β-cell transdifferentiation, neogenesis, and stem cell differentiation, which have nucleated multiple promising therapeutic strategies.
[Endocrinology]

Abstract

Insight into the Physiological and Pathological Roles of the Aryl Hydrocarbon Receptor Pathway in Glucose Homeostasis, Insulin Resistance, and Diabetes Development

Investigators provide insight into the physiological and pathological role of AhR and its regulated enzymes, such as cytochrome P450 1A1 and CYP1B1 in both types of diabetes.
[Cellular & Molecular Biology Letters]

Full Article

INDUSTRY AND POLICY NEWS

Inversago Pharma Doses First Patient in Phase II Trial of INV-202, an Oral, Peripherally-acting CB1 Inverse Agonist, in Patients with Diabetic Kidney Disease

Inversago Pharma, Inc. announced that the first patient has been dosed with INV-202 in a Phase II clinical trial in subjects with diabetic kidney disease.
[Inversago Pharma, Inc. (BusinessWire, Inc.)]

Press Release

Wayne State Researchers Aim to Improve the Future of Diabetes Therapy

A team of researchers from Wayne State University received a nearly $2.7 million government grant under the auspices of the National Institute of Diabetes and Digestive and Kidney Diseases for the study, “Infusion device optimization by addressing root causes of the inflammatory response.”
[Wayne State University]

Full Article

FEATURED EVENT

Pancreatic Cell News Volume 14.47 | Dec 6 2022

Neuronal-Epithelial Cross-Talk Drives Acinar Specification via NRG1-ERBB3-mTORC2 Signaling

Extracellular SQSTM1 Exacerbates Acute Pancreatitis by Activating Autophagy-Dependent Ferroptosis

Glycemic Control Releases Regenerative Potential of Pancreatic Beta Cells Blocked by Severe Hyperglycemia

RNA Binding Protein HUD Mediates the Crosstalk between β Cells and Islet Endothelial Cells by the Regulation of Endostatin and Serpin E1 Expression

Diphenyl Ether Derivatives as Novel GPR120 Agonists for the Treatment of Type 2 Diabetes Mellitus

Elevated FSP1 Protects KRAS-Mutated Cells from Ferroptosis during Tumor Initiation

BRAF^V600E in Colorectal Cancer Reduces Sensitivity to Oxidative Stress and Promotes Site-Specific Metastasis by Stimulating Glutathione Synthesis

Assessment of Stromal SCD-Induced Drug Resistance of PDAC Using 3D-Printed zPDX Model Chips

Mesenchymal-Endothelial Nexus in Breast Cancer Spheroids Induces Vasculogenesis and Local Invasion in a CAM Model

Novel Histone Post-Translational Modifications in Diabetes and Complications of Diabetes: The Underlying Mechanisms and Implications

Therapeutic Strategies Targeting Pancreatic Islet β-Cell Proliferation, Regeneration, and Replacement

Insight into the Physiological and Pathological Roles of the Aryl Hydrocarbon Receptor Pathway in Glucose Homeostasis, Insulin Resistance, and Diabetes Development

Inversago Pharma Doses First Patient in Phase II Trial of INV-202, an Oral, Peripherally-acting CB1 Inverse Agonist, in Patients with Diabetic Kidney Disease

Wayne State Researchers Aim to Improve the Future of Diabetes Therapy

Next Generation Antibody Therapeutics: From Discovery to Patient

> See All Events

PhD Positions – Biomedical Sciences

Research Associate – Type 1 Diabetes Mellitus

Investigators – Liver Diseases

Senior Program Associate – Science in the City

Postdoctoral Research Associate – Medical Physiology

> See All Jobs